Compounds > pyrazolanthrone
Page last updated: 2024-08-18

pyrazolanthrone and dasatinib

pyrazolanthrone has been researched along with dasatinib in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A1
Dong, Q; Ge, J; Huang, Q; Tian, S; Zhao, L; Zhu, H1
Jiao, B; Li, D; Liao, L; Liu, M; Liu, P; Ren, R; Wang, P; Xia, Z; Xiao, X; Zhang, X1

Reviews

1 review(s) available for pyrazolanthrone and dasatinib

ArticleYear
Kinase Inhibitors as Underexplored Antiviral Agents.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses

2022

Other Studies

4 other study(ies) available for pyrazolanthrone and dasatinib

ArticleYear
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Integrative identification of unexpected kinase-inhibitor interactions in the MAPK-mediated proliferation and differentiation of Mc3T3-E1 osteoblasts.
    General physiology and biophysics, 2019, Volume: 38, Issue:1

    Topics: Aniline Compounds; Animals; Anthracenes; Cell Differentiation; Cell Line; Cell Proliferation; Dasatinib; Imidazoles; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Nitriles; Osteoblasts; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines

2019
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
    Journal of hematology & oncology, 2020, 06-18, Volume: 13, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Animals; Anthracenes; Antineoplastic Combined Chemotherapy Protocols; Azepines; Benzamides; Cell Line, Tumor; Dasatinib; Drug Screening Assays, Antitumor; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Neoplasm Proteins; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridines; Pyrimidines; Radiation Chimera; Random Allocation; RNA Interference; RNA, Small Interfering; Signal Transduction; Triazoles

2020